Diabetes-mediated middle cerebral artery remodeling is restored by linagliptin: Interaction with the vascular smooth muscle cell endothelin system

Life Sciences

Volumn 159, Issue , 2016, Pages 76-82

  Yasir, Abdul ^a,b   Hardigan, Trevor ^b   Ergul, Adviye ^a,b  

^a AUGUSTA UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Diabetes; Endothelin; Linagliptin and brain vascular smooth muscle cells

Indexed keywords

ENDOTHELIN 1; GLUCOSE; LINAGLIPTIN; METFORMIN; ANTIDIABETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LYSATE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE CEREBRAL ARTERY; MORPHOMETRICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN SECRETION; RAT; TREATMENT DURATION; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PATHOLOGY; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIN-1; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; LINAGLIPTIN; MALE; MIDDLE CEREBRAL ARTERY; MUSCLE, SMOOTH, VASCULAR; RATS; VASCULAR REMODELING;

EID: 84959890689     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.02.096     Document Type: Article

References (36)

1. [1] Ergul, A., Abdelsaid, M., Fouda, A.Y., Fagan, S.C., Cerebral neovascularization in diabetes: implications for stroke recovery and beyond. J. Cereb. Blood Flow Metab. 34 (2014), 553–563.
2. [2] Ergul, A., Kelly-Cobbs, A., Abdalla, M., Fagan, S.C., Cerebrovascular complications of diabetes: focus on stroke. Endocr. Metab. & Immune Disord. Drug Targets 12 (2012), 148–158.
3. [3] Phipps, M.S., Jastreboff, A.M., Furie, K., Kernan, W.N., The diagnosis and management of cerebrovascular disease in diabetes. Curr. Diab. Rep. 12 (2012), 314–323.
4. [4] de Marco, R., Locatelli, F., Zoppini, G., Verlato, G., Bonora, E., Muggeo, M., Cause-specific mortality in type 2 diabetes. The Verona diabetes study. Diabetes Care 22 (1999), 756–761.
5. [5] Abdelsaid, M., Kaczmarek, J., Coucha, M., Ergul, A., Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control. Life Sci. 118 (2014), 268–273.
6. [6] Khan, Z.A., Chakrabarti, S., Endothelins in chronic diabetic complications. Can. J. Physiol. Pharmacol. 81 (2003), 622–634.
7. [7] Matsumoto, T., Yoshiyama, S., Kobayashi, T., Kamata, K., Mechanisms underlying enhanced contractile response to endothelin-1 in diabetic rat basilar artery. Peptides 25 (2004), 1985–1994.
8. [8] Kohner, E.M., Patel, V., Rassam, S.M., Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes 44 (1995), 603–607.
9. [9] Abdelsaid, M., Ma, H., Coucha, M., Ergul, A., Late dual endothelin receptor blockade with bosentan restores impaired cerebrovascular function in diabetes. Life Sci. 118 (2014), 263–267.
10. [10] Harris, A.K., Hutchinson, J.R., Sachidanandam, K., Johnson, M.H., Dorrance, A.M., Stepp, D.W., Fagan, S.C., Ergul, A., Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes 54 (2005), 2638–2644.
11. [11] Kelly-Cobbs, A.I., Harris, A.K., Elgebaly, M.M., Li, W., Sachidanandam, K., Portik-Dobos, V., Johnson, M., Ergul, A., Endothelial endothelin B receptor-mediated prevention of cerebrovascular remodeling is attenuated in diabetes because of up-regulation of smooth muscle endothelin receptors. J. Pharmacol. Expe. Ther. 337 (2011), 9–15.
12. [12] Sachidanandam, K., Harris, A., Hutchinson, J., Ergul, A., Microvascular versus macrovascular dysfunction in type 2 diabetes: differences in contractile responses to endothelin-1. Exp. Biol. Med. 231 (2006), 1016–1021.
13. [13] Schneider, M.P., Boesen, E.I., Pollock, D.M., Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Ann. Rev. Pharmacol. Toxicol. 47 (2007), 731–759.
14. [14] Pollock, D.M., Dissecting the complex physiology of endothelin: new lessons from genetic models. Hypertension 56 (2010), 31–33.
15. [15] Sachidanandam, K., Hutchinson, J.R., Elgebaly, M.M., Mezzetti, E.M., Dorrance, A.M., Motamed, K., Ergul, A., Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296 (2009), R952–R959.
16. [16] Guedes, E.P., Hohl, A., de Melo, T.G., Lauand, F., Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment. Diabetol. Metab. Syndr., 5, 2013, 25.
17. [17] Ayaori, M., Iwakami, N., Uto-Kondo, H., Sato, H., Sasaki, M., Komatsu, T., Iizuka, M., Takiguchi, S., Yakushiji, E., Nakaya, K., Yogo, M., Ogura, M., Takase, B., Murakami, T., Ikewaki, K., Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J. Am. Heart Assoc., 2, 2013, e003277.
18. [18] Rautureau, Y., Schiffrin, E.L., Endothelin in hypertension: an update. Curr. Opin. Nephrol. Hypertens. 21 (2012), 128–136.
19. [19] Ergul, A., Endothelin-1 and diabetic complications: focus on the vasculature. Pharmacol. Res. 63 (2011), 477–482.
20. [20] Amiri, F., Virdis, A., Neves, M.F., Iglarz, M., Seidah, N.G., Touyz, R.M., Reudelhuber, T.L., Schiffrin, E.L., Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110 (2004), 2233–2240.
21. [21] Sachidanandam, K., Portik-Dobos, V., Harris, A.K., Hutchinson, J.R., Muller, E., Johnson, M.H., Ergul, A., Evidence for vasculoprotective effects of ETB receptors in resistance artery remodeling in diabetes. Diabetes 56 (2007), 2753–2758.
22. [22] Kelly-Cobbs, A., Elgebaly, M.M., Li, W., Ergul, A., Pressure-independent cerebrovascular remodelling and changes in myogenic reactivity in diabetic Goto–Kakizaki rat in response to glycaemic control. Acta Physiol. 203 (2011), 245–251.
23. [23] Rubanyi, G.M., Polokoff, M.A., Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 46 (1994), 325–415.
24. [24] Resink, T.J., Hahn, A.W., Scott-Burden, T., Powell, J., Weber, E., Buhler, F.R., Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 168 (1990), 1303–1310.
25. [25] Yu, J.C., Davenport, A.P., Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells. Br. J. Pharmacol. 114 (1995), 551–557.
26. [26] Yu, J.C., Davenport, A.P., Regulation of endothelin receptor expression in vascular smooth-muscle cells. J. Cardiovasc. Pharmacol. 26:Suppl. 3 (1995), S348–S350.
27. [27] Sachidanandam, K., Portik-Dobos, V., Kelly-Cobbs, A.I., Ergul, A., Dual endothelin receptor antagonism prevents remodeling of resistance arteries in diabetes. Can. J. Physiol. Pharmacol. 88 (2010), 616–621.
28. [28] Avedanian, L., Riopel, J., Bkaily, G., Nader, M., D'Orleans-Juste, P., Jacques, D., ETA receptors are present in human aortic vascular endothelial cells and modulate intracellular calcium. Can. J. Physiol. Pharmacol. 88 (2010), 817–829.
29. [29] Jafri, F., Ergul, A., Nuclear localization of endothelin-converting enzyme-1: subisoform specificity. Arterioscler. Thromb. Vasc. Biol. 23 (2003), 2192–2196.
30. [30] Branco, A.F., Bruce, G.A., G protein-coupled receptor signaling in cardiac nuclear membrane. Cardiovasc. Pharmacol. 65–2 (2015), 101–109.
31. [31] Panchapakesan, U., Mather, A., Pollock, C., Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin. Sci. 124 (2013), 17–26.
32. [32] Yeager, M.E., Belchenko, D.D., Nguyen, C.M., Colvin, K.L., Ivy, D.D., Stenmark, K.R., Endothelin-1, the unfolded protein response, and persistent inflammation: role of pulmonary artery smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 46 (2012), 14–22.
33. [33] Virdis, A., Schiffrin, E.L., Vascular inflammation: a role in vascular disease in hypertension?. Curr. Opin. Nephrol. Hypertens. 12 (2003), 181–187.
34. [34] Aroor, A.R., Sowers, J.R., Bender, S.B., Nistala, R., Garro, M., Mugerfeld, I., Hayden, M.R., Johnson, M.S., Salam, M., Whaley-Connell, A., Demarco, V.G., Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology 154 (2013), 2501–2513.
35. [35] Shah, Z., Pineda, C., Kampfrath, T., Maiseyeu, A., Ying, Z., Racoma, I., Deiuliis, J., Xu, X., Sun, Q., Moffatt-Bruce, S., Villamena, F., Rajagopalan, S., Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vasc. Pharmacol. 55 (2011), 2–9.
36. [36] Salheen, S.M., Panchapakesan, U., Pollock, C.A., Woodman, O.L., The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose. Pharmacol. Res. 94 (2015), 26–33.